Is phosphodiesterase type 5 inhibitor use associated with condom breakage? CommentaryCROSBY, R; YARBER, W. L; SANDERS, S. A et al.Sexually transmitted infections. 2009, Vol 85, Num 5, pp 404-406, issn 1368-4973, 3 p.Article

Role of Growth Factors in Improved Skin Flap Viability Caused by Phosphodiesterase-5 InhibitorBANDERA, Bradley C; PHAM, Thach; HILL-PRYOR, Crystal et al.The American surgeon. 2010, Vol 76, Num 6, pp 614-617, issn 0003-1348, 4 p.Article

Transitiometric analysis of solid II/solid I transition in anhydrous theophyllineLEGENDRE, Bernard; RANDZIO, Stanislaw L.International journal of pharmaceutics. 2007, Vol 343, Num 1-2, pp 41-47, issn 0378-5173, 7 p.Article

Modulation of Morphine-induced Antinociception in Acute and Chronic Opioid Treatment by IbudilastLILIUS, Tuomas O; RAUHALA, Pekka V; KAMBUR, Oleg et al.Anesthesiology (Philadelphia). 2009, Vol 111, Num 6, pp 1356-1364, issn 0003-3022, 9 p.Article

Pyrazoloquinolines as PDE10A inhibitors: Discovery of a tool compoundMCELROY, William T; ZHENG TAN; XIAOPING ZHANG et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 3, pp 1335-1339, issn 0960-894X, 5 p.Article

Intérêt thérapeutique d'un inhibiteur de la phosphodiestérase de type 5 et d'un antagoniste sélectif des récepteurs de l' endothéline AALLANORE, Yannick.La Revue de médecine interne (Paris). 2010, Vol 31, pp 8-9, issn 0248-8663, 2 p., HS1Article

Phosphodiesterase inhibitors block the acceleration of skin permeability barrier repair by red lightGOTO, Makiko; IKEYAMA, Kazuyuki; TSUTSUMI, Moe et al.Experimental dermatology. 2011, Vol 20, Num 7, pp 568-571, issn 0906-6705, 4 p.Article

Erectile Dysfunction and Cardiovascular Disease : Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both ConditionsNEHRA, Ajay.Mayo Clinic proceedings. 2009, Vol 84, Num 2, pp 139-148, issn 0025-6196, 10 p.Article

Enhancement of transdermal delivery of theophylline using microemulsion vehicleZHAO, X; LIU, J. P; ZHANG, X et al.International journal of pharmaceutics. 2006, Vol 327, Num 1-2, pp 58-64, issn 0378-5173, 7 p.Article

Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in menSTIRBAN, Alin; TAMLER, Ronald; ANDREI VERESIU, Loan et al.Journal of men's health (Print). 2011, Vol 8, Num 2, pp 109-118, issn 1875-6867, 10 p.Article

Phosphodiesterase-5 inhibitors and rosacea : report of 10 casesIOANNIDES, D; LAZARIDOU, E; APALLA, Z et al.British journal of dermatology (1951). 2009, Vol 160, Num 3, pp 719-720, issn 0007-0963, 2 p.Article

How to optimise treatment of erectile dysfunction above and beyond the beneficial effects of a phosphodiesterase type 5 inhibitorGOOREN, Louis.Journal of men's health. 2008, Vol 5, Num 2, pp 163-170, 8 p.Article

CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophyllineFUKAMI, Tatsuki; NAKAJIMA, Miki; SAKAI, Haruko et al.Drug metabolism and disposition. 2007, Vol 35, Num 3, pp 335-339, issn 0090-9556, 5 p.Article

Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+ ) -2 -[4 -({[2 -(benzo[1,3 ]dioxol -5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and humanKALGUTKAR, Amit S; BO FENG; DUIGNAN, David B et al.Drug metabolism and disposition. 2007, Vol 35, Num 11, pp 2111-2118, issn 0090-9556, 8 p.Article

Theophylline inhibits the cough reflex through a novel mechanism of actionDUBUIS, Eric; WORTLEY, Michael A; GRACE, Megan S et al.Journal of allergy and clinical immunology. 2014, Vol 133, Num 6, pp 1588-1598, issn 0091-6749, 11 p.Article

Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation?AVERSA, A; FRANCOMANO, D; BRUZZICHES, R et al.International journal of impotence research. 2011, Vol 23, Num 1, pp 17-23, issn 0955-9930, 7 p.Article

Erectile dysfunction and heart failure : the role of phosphodiesterase type 5 inhibitorsAL-AMERI, H; KLONER, R. A.International journal of impotence research. 2009, Vol 21, Num 3, pp 149-157, issn 0955-9930, 9 p.Article

Ibudilast in healthy volunteers : safety, tolerability and pharmacokinetics with single and multiple dosesROLAN, Paul; GIBBONS, Jacqueline A; LIN HE et al.British journal of clinical pharmacology. 2008, Vol 66, Num 6, pp 792-801, issn 0306-5251, 10 p.Article

New multipeg-conjugated theophylline derivatives : Synthesis and pharmacological evaluationsZACCHIGNA, Marina; DI LUCA, Gabriella; CATENI, Francesca et al.European journal of pharmaceutical sciences. 2007, Vol 30, Num 3-4, pp 343-350, issn 0928-0987, 8 p.Article

Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction : results from the Erectile Dysfunction Observational StudyHATZICHRISTOU, D; HARE, J. M; MARTIN-MORALES, A et al.International journal of clinical practice (Esher). 2007, Vol 61, Num 11, pp 1850-1862, issn 1368-5031, 13 p.Article

The ability of phosphodiesterase-5 inhibitors sildenafil and ordonafil to reverse L-NAME induced cardiac hypertrophy in the rabbit: possible role of calcineurin and p38ZEIDAN, Asad; SIAM, Aiad; AL KAABBA, Abdulaziz et al.Canadian journal of physiology and pharmacology. 2012, Vol 90, Num 9, pp 1247-1255, issn 0008-4212, 9 p.Conference Paper

Cyclic GMP-Hydrolyzing PhosphodiesterasesFRANCIS, Sharron H; CORBIN, Jackie D; BISCHOFF, Erwin et al.Handbook of experimental pharmacology. 2009, Vol 191, pp 367-408, issn 0171-2004, 42 p.Article

Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database studyKIRBY, M. G; SCHNETZLER, G; ZOU, K. H et al.International journal of clinical practice (Esher). 2011, Vol 65, Num 7, pp 797-806, issn 1368-5031, 10 p.Article

Calorimetric determination of dissolution enthalpy with a novel flow-through methodLEHTO, Vesa-Pekka; TENHO, Mikko; HÄMÄLÄINEN, Olli-Pekka et al.Journal of pharmaceutical and biomedical analysis. 2010, Vol 53, Num 4, pp 821-825, issn 0731-7085, 5 p.Article

Accelerated Dissolution Testing for Controlled Release Microspheres Using the Flow-Through Dissolution ApparatusCOLLIER, Jarrod W; THAKARE, Mohan; GARNER, Solomon T et al.Pharmaceutical development and technology. 2009, Vol 14, Num 1, pp 9-17, issn 1083-7450, 9 p.Article